Existing clinical biomarkers, including myocardial necrosis (cardiac troponin I, cTnI), stress (B-type natriuretic peptide, BNP), and inflammation (high-sensitivity C-reactive protein, hs-CRP), are insufficient for precise HF prediction in patients with AMI5. This evidence concerns the gene TNNI3 and necrosis.